Subsequent offering - subscription period ends today
(Thomson Reuters ONE) -
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE IN THE PROSPECTUS.
Tromsø, Norway, 10 February 2011 - Biotec Pharmacon ASA
(OSE: Biotec)
Reference is made to the announcement dated 23 December 2010 and the prospectus
dated 27 January 2011 (the "Prospectus") concerning the subsequent offering of
up to 1,200,000 shares in Biotec Pharmacon ASA at a subscription price of NOK
6.30.
The subscription period for the subsequent offering will end today, 10 February
2011, at 17:30 CET.
The Prospectus and the application form for the subsequent offering is available
at the Company's website www.biotec.no and at the websites of the
manager, SEB Enskilda (www.sebenskilda.no).
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act).
For further information, please contact:
Svein W. F. Lien, CEO
Mobile: +47 92 28 93 23
Arvid Vangen, VP Finance & Administration
Phone: +47 77 64 89 12
Mobile: +47 95 03 87 94
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures
new immunomodulatory products and cold adapted marine enzymes. The company
focuses on new and effective solutions within wound care, cancer therapies and
other immune related disease areas, and aspires to become a leading supplier of
novel enzymes for diagnostics and genetic research.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
[HUG#1487585]
Unternehmensinformation / Kurzprofil:
Datum: 10.02.2011 - 10:26 Uhr
Sprache: Deutsch
News-ID 51314
Anzahl Zeichen: 2380
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Subsequent offering - subscription period ends today"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
